Effects of Postbiotics on Mood Disorders in Korean Adults

Hanyang University

Status: Active, not recruiting

Conditions: Mood Disorder

Treatments: Dietary Supplement: placebo; Dietary Supplement: postbiotics

Study type: Interventional

Funder types: Other

Identifiers

NCT06982599

HYUIRB-202503-008 (Other Identifier)

POST-LB-KR

Details and patient eligibility

About

This study was conducted to investigate effects of postbiotics on mood disorders in korean adults

Full description

This study is an 8-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial. 52 participants were randomly assigned to either the postbiotics intervention group or a placebo group. The study aimed to evaluate the effects of postbiotics on mood disorders in Korean adults, comparing pre- and post-intervention mood profiles.

Enrollment: 52 estimated patients

Sex: All

Ages: 19 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults aged between 19 and 39 years at the time of screening.
• BMI between 18.5 and 30 at the time of screening.
• CES-D (Center for Epidemiologic Studies Depression Scale) score of 16 or higher.
• Ability to access and respond to the survey via an online link.

Exclusion criteria

• Participation in any human clinical trial within the past 3 months before screening.
• History of antipsychotic medication treatment within the past 3 months before screening.
• Presence of chronic diseases, including cardiovascular, endocrine, immune, respiratory, hepatobiliary, renal and urological, neurological, musculoskeletal, inflammatory, hematological, oncological, or gastrointestinal disorders.
• Use of medications or health supplements related to gut health and mood disorders (e.g., antibiotics, laxatives, antidiarrheals, prebiotics, probiotics, postbiotics, anxiolytics, antidepressants, etc.) within 1 month prior to participation in the study.
• History of significant hypersensitivity to postbiotics or starch.
• Alcohol addiction, drug abuse, or suspicion of substance misuse.
• Pregnant or breastfeeding women.
• Any other reasons that the study investigator deems the participant unsuitable for participation.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

52 participants in 2 patient groups, including a placebo group

postbiotics

Experimental group

Description:

3 capsules/day postbiotics (20 × 10\^9 CFU/day) for 8 weeks

Treatment:

Dietary Supplement: postbiotics

Placebo

Placebo Comparator group

Description:

3 capsules/day placebo for 8 weeks

Treatment:

Dietary Supplement: placebo